

Organization Applicant

-----

Street :  
City :  
State :  
Country :  
PostalCode :  
PhoneNumber :  
FaxNumber :  
EmailAddress :

<110> OrganizationName : Novo Nordisk A/S

Application Project

-----

<120> Title : Insulin analogues with an acyl and alkylene glycol moiety  
<130> AppFileReference : 7701.204-WO  
<140> CurrentAppNumber :  
<141> CurrentFilingDate : \_\_\_\_-\_\_-\_\_

Sequence

-----

<213> OrganismName : Artificial  
<400> PreSequenceString :  
GIVEQCCTSI CSLYQLENYC N 21  
<212> Type : PRT  
<211> Length : 21  
SequenceName : 1  
SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial  
<400> PreSequenceString :  
FVNQHLCGSH LVEALYLVC G ERGFFYTPR 29  
<212> Type : PRT  
<211> Length : 29  
SequenceName : 2  
SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial  
<400> PreSequenceString :  
GIVEQCCTSI CSLEQLENYC N 21  
<212> Type : PRT  
<211> Length : 21  
SequenceName : 3  
SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial  
<400> PreSequenceString :  
FVNQHLCGSH LVEALYLVC G ERGFHYTPR 29  
<212> Type : PRT  
<211> Length : 29  
SequenceName : 4

SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial

<400> PreSequenceString :

GIVEQCCTSI CSLYQLELYC N

21

<212> Type : PRT

<211> Length : 21

SequenceName : 5

SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial

<400> PreSequenceString :

GIVEQCCHSI CSLYQLENYC N

21

<212> Type : PRT

<211> Length : 21

SequenceName : 6

SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial

<400> PreSequenceString :

FVNQHLCGSH LVEALYLVCG ERGFFYTER

29

<212> Type : PRT

<211> Length : 29

SequenceName : 7

SequenceDescription :

Sequence

-----

<213> OrganismName : Artificial

<400> PreSequenceString :

FVNQHLCGSH LVEALYLVCG ERGFFYTP

28

<212> Type : PRT

<211> Length : 28

SequenceName : 8

SequenceDescription :